NZ516507A - Growth hormone formulations that are resistant to crystallisation - Google Patents

Growth hormone formulations that are resistant to crystallisation

Info

Publication number
NZ516507A
NZ516507A NZ516507A NZ51650700A NZ516507A NZ 516507 A NZ516507 A NZ 516507A NZ 516507 A NZ516507 A NZ 516507A NZ 51650700 A NZ51650700 A NZ 51650700A NZ 516507 A NZ516507 A NZ 516507A
Authority
NZ
New Zealand
Prior art keywords
growth hormone
resistant
crystallisation
hormone formulations
formulation
Prior art date
Application number
NZ516507A
Other languages
English (en)
Inventor
Bernhard Siebold
John Stevens
Original Assignee
Grandis Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ516507(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9916252.1A external-priority patent/GB9916252D0/en
Priority claimed from GBGB9918902.9A external-priority patent/GB9918902D0/en
Application filed by Grandis Biotech Gmbh filed Critical Grandis Biotech Gmbh
Publication of NZ516507A publication Critical patent/NZ516507A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
NZ516507A 1999-07-12 2000-07-11 Growth hormone formulations that are resistant to crystallisation NZ516507A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9916252.1A GB9916252D0 (en) 1999-07-12 1999-07-12 Growth hormone formulation
GBGB9918902.9A GB9918902D0 (en) 1999-08-12 1999-08-12 Growth hormone formulation
PCT/GB2000/002664 WO2001003741A1 (en) 1999-07-12 2000-07-11 Growth hormone formulations

Publications (1)

Publication Number Publication Date
NZ516507A true NZ516507A (en) 2004-02-27

Family

ID=26315757

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ516507A NZ516507A (en) 1999-07-12 2000-07-11 Growth hormone formulations that are resistant to crystallisation

Country Status (25)

Country Link
US (1) US20060029635A1 (https=)
EP (1) EP1194170B1 (https=)
JP (3) JP2003504346A (https=)
KR (1) KR20020031388A (https=)
CN (1) CN1360506A (https=)
AR (1) AR024728A1 (https=)
AT (1) ATE386501T1 (https=)
AU (1) AU775107C (https=)
BR (1) BR0013162A (https=)
CA (1) CA2378949C (https=)
CZ (1) CZ200260A3 (https=)
DE (1) DE60038118T2 (https=)
ES (1) ES2300268T3 (https=)
HK (1) HK1046358A1 (https=)
HU (1) HUP0202189A3 (https=)
IL (2) IL147253A0 (https=)
MX (1) MXPA02000404A (https=)
NO (1) NO20020151L (https=)
NZ (1) NZ516507A (https=)
PL (1) PL353238A1 (https=)
SI (1) SI1194170T1 (https=)
SK (1) SK252002A3 (https=)
TR (1) TR200200034T2 (https=)
TW (1) TWI247608B (https=)
WO (1) WO2001003741A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162711A1 (en) * 1996-04-24 2003-08-28 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) * 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
GB2371227A (en) * 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
CA2491682A1 (en) * 2002-07-09 2004-01-15 Sandoz Ag Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine
JP4949828B2 (ja) * 2003-03-18 2012-06-13 アレス トレーディング ソシエテ アノニム 溶液中での成長ホルモンの安定化
JP2007506683A (ja) * 2003-09-25 2007-03-22 カンジェーン コーポレイション ヒト成長ホルモン剤およびその調整方法と使用方法
US8338374B2 (en) 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
US7662393B2 (en) * 2004-04-07 2010-02-16 Ares Trading S.A. Liquid growth hormone formulation and method of use
US8293532B2 (en) 2009-03-26 2012-10-23 Dow AgroSciences, L.L.C. Method and apparatus for tissue transfer
KR101614983B1 (ko) * 2009-11-17 2016-04-22 입센 파마 에스.에이.에스 Ｈｇｈ 및 ｒｈｉｇｆ―１의 조합물을 위한 제제
JP6363949B2 (ja) 2011-07-25 2018-07-25 サンド アクチェンゲゼルシャフト 少なくとも中性塩および生物薬学的タンパク質を含む、水性製剤
JP2013231030A (ja) * 2012-04-30 2013-11-14 Sun Pharmaceutical Industries Ltd リュープロリド注射剤
JP6001401B2 (ja) * 2012-09-28 2016-10-05 ユニ・チャーム株式会社 ウェットティッシュ用薬液及びウェットティッシュ
US10647819B2 (en) 2015-12-10 2020-05-12 Mitsubishi Gas Chemical Company, Inc. Photocurable composition and optical material
WO2018142514A1 (ja) * 2017-02-01 2018-08-09 協和発酵キリン株式会社 ダルベポエチンを含む液体医薬組成物
WO2020004368A1 (ja) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
WO2022104389A1 (en) * 2020-11-16 2022-05-19 W. L. Gore & Associates, Inc. Formulations, methods, and pre-filled multi-dose injection devices without cloud point
CN112494638B (zh) * 2020-12-22 2023-12-19 深圳科兴药业有限公司 一种人生长激素注射剂组合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
DE3325223A1 (de) * 1983-07-13 1985-01-24 Hoechst Ag, 6230 Frankfurt Gegen denaturierung bestaendige, waessrige proteinloesungen, verfahren zu ihrer herstellung und ihre verwendung
JPS6270319A (ja) * 1985-07-30 1987-03-31 インタ−ナシヨナル・ミネラルズ・アンド・ケミカル・コ−ポレイシヨン 成長促進ホルモンの安定化
US4857505A (en) * 1987-03-09 1989-08-15 American Cyanamid Company Sustained release compositions for parenteral administration and their use
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
CA1331133C (en) * 1988-03-01 1994-08-02 Michael Jon Pikal Pharmaceutical growth hormone formulations
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
ES2073173T3 (es) * 1990-09-21 1995-08-01 Novo Nordisk As Cubierta adaptadora.
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
ES2153385T5 (es) * 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5610134A (en) * 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
JPH0892125A (ja) * 1994-09-21 1996-04-09 Nippon Chem Res Kk 水性医薬組成物
SE9502927D0 (sv) * 1995-08-24 1995-08-24 Pharmacia Ab Solution containing IGF-I
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
WO1997029776A1 (en) * 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
ZA9711731B (en) * 1996-12-31 1998-07-01 Monsanto Co Aqueous glycerol formulations of somatotropin
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物

Also Published As

Publication number Publication date
WO2001003741B1 (en) 2001-04-19
DE60038118T2 (de) 2009-03-05
HUP0202189A2 (en) 2002-10-28
EP1194170A1 (en) 2002-04-10
CA2378949C (en) 2015-03-31
JP2014208656A (ja) 2014-11-06
AU775107C (en) 2005-02-24
TR200200034T2 (tr) 2002-05-21
DE60038118D1 (de) 2008-04-03
NO20020151D0 (no) 2002-01-11
AR024728A1 (es) 2002-10-23
ATE386501T1 (de) 2008-03-15
BR0013162A (pt) 2002-05-28
JP5941496B2 (ja) 2016-06-29
CZ200260A3 (cs) 2002-04-17
KR20020031388A (ko) 2002-05-01
PL353238A1 (en) 2003-11-03
ES2300268T3 (es) 2008-06-16
TWI247608B (en) 2006-01-21
NO20020151L (no) 2002-03-12
AU5997500A (en) 2001-01-30
CN1360506A (zh) 2002-07-24
SI1194170T1 (sl) 2008-10-31
WO2001003741A1 (en) 2001-01-18
IL147253A (en) 2007-07-24
HUP0202189A3 (en) 2003-07-28
EP1194170B1 (en) 2008-02-20
US20060029635A1 (en) 2006-02-09
MXPA02000404A (es) 2004-05-21
HK1046358A1 (zh) 2003-01-10
CA2378949A1 (en) 2001-01-18
SK252002A3 (en) 2002-06-04
JP2003504346A (ja) 2003-02-04
AU775107B2 (en) 2004-07-15
IL147253A0 (en) 2002-08-14
JP2012051891A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
NZ516507A (en) Growth hormone formulations that are resistant to crystallisation
SI9420048B (sl) Farmacevtske formulacije živčnega rastnega faktorja
CA2201749A1 (en) Stable aqueous alfa interferon solution formulations
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
EP1426058A3 (de) Flüssige Interferon-Beta Formulierungen
WO1992019104A3 (en) Fatty acid based compositions for the control of established plant infections
MX9800438A (es) Formulaciones liquidas que contienen gonadotropina.
CA2413334A1 (en) Stabilized interleukin 2
CA2049822A1 (en) Stable aqueous preparation
CA2452638A1 (en) Optimised formulation of tobramycin for aerosolization
CA2023563A1 (en) Stable injectable pharmaceutical formulation for folic acid and leucovorin salts and method
CA2379468A1 (en) Pesticide formulations containing phosphate ester surfactant and alkoxylated lignosulfonate
CA2226548A1 (en) Lyophilized hepatocyte growth factor preparations
NZ312352A (en) Surfactants providing enhanced efficacy and/or rainfastness to pesticide formulations
CA2378425A1 (en) Aqueous pharmaceutical formulation of moxifloxacin or salts thereof
MX9603515A (es) Preparacion farmaceutica que contiene activadores de plasminogeno.
NZ334836A (en) Liquid alendronate formulations and their use in preventing bone resorption
WO2001076593A3 (en) Bile secretion promoting composition a 15-keto prostaglandin
CA2072797A1 (en) Use of tri (n-butyl) phosphate at low ph in solutions of biologically active proteins for enhanced virucidal activity
AU2001288229A1 (en) An advantageous carrier solution for vitrifiable concentrations of cryoprotectants, and compatible cryoprotectant mixtures
FR2694159B1 (fr) Composition comprenant de la choline, ou ses dérivés ou ses sels, et utilisable dans le domaine agricole pour favoriser la photosynthèse des plantes.
JPH07187902A (ja) 切花活性剤
AU1022688A (en) Antibacterial lyophilized preparation
RU94032143A (ru) Композиция, содержащая препарат коагуляционного фактора viii, способ ее получения и применение поверхностно-активного вещества в качестве стабилизатора
AU621677B2 (en) Stable aqueous solutions of primycin, pharmaceutical and cosmetic compositions containing these solutions and process for preparing same

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)